HRQoL Data Showcase Impact of Prophylactic Regimens With Neratinib in ExteNET and CONTROL Analyses for HER2+ Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Monday, May 13, 2019
Suzette Delaloge, MD

Suzette Delaloge, MD

Extended adjuvant treatment with neratinib (Nerlynx) given with or without antidiarrheal prophylaxis was associated with decreases in health-related quality of life (HRQoL) in patients with HER2-positive breast cancer, according to results of an analysis of the ExteNET and CONTROL trials.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x